Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00250159 · ClinicalTrials.gov registry record

Natural History Study of Patients With Excess Androgen

A clinical trial of Congenital Adrenal Hyperplasia (CAH) and Familial Male-Limited Precocious Puberty (FMPP), sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Recruiting
Registry status
3,000
Enrollment target
2
Study locations

NCT00250159 is a study of Congenital Adrenal Hyperplasia (CAH) and Familial Male-Limited Precocious Puberty (FMPP) that is actively recruiting participants, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 3,000 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00250159, a study of Congenital Adrenal Hyperplasia (CAH) and Familial Male-Limited Precocious Puberty (FMPP), is actively recruiting participants, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

RECRUITING
Registry status
3,000 participants
Enrollment target
2
Study locations

Study Summary

This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effects of too much androgen and describe problems associated with it. Too much androgen in childhood, if untreated, results in rapid growth and early puberty with early cessation of growth and short stature in adulthood. Too much androgen in adulthood may result in infertility, and women may have excess facial hair, acne and a more male-like appearance. Excess androgen may also affect mood and behavior and possibly the secretion of other hormones, such as insulin. Two genetic diseases that result in early childhood androgen excess are congenital adrenal hyperplasia (CAH) and familial male-limited precocious puberty (FMPP). Patients with known or suspected CAH due to 21-hydroxylase deficiency, 11- hydroxylase deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency and males with known or suspected FMPP may be eligible for this study. Patients with both classic and non-classic CAH are eligible, and patients with androgen excess of unknown cause may be eligible. Participants undergo the following procedures: * Medical history and physical examination. * Fasting blood tests for analysis of hormones, blood chemistries including blood sugar and cardiovascular risk factors such as lipids. * Oral glucose tolerance test for patients with elevated insulin levels. For this test, a catheter (plastic tube) is placed in a vein in the patient's arm. The patient drinks a sugar-containing fluid and blood samples are collected through the catheter at intervals starting with drinking the solution, and then 30, 60 and 120 minutes after drinking the solution. * 24-hour urine collection to measure hormone levels in the urine. * DNA testing for patients with 21-hydroxylase deficiency to help identify the type of genetic mutation responsible for the disease. * X-ray of the left hand to measure bone age in growing children. The

Study Locations (2)

District of Columbia

  • Medstar Washington Hospital Center - Washington D.C.

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2006-01-02

What the Registry Record Tells You About NCT00250159

The ClinicalTrials.gov registry entry for NCT00250159 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Congenital Adrenal Hyperplasia (CAH) appearing as the primary indexed condition, and to 0 interventions.

NCT00250159 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT00250159 about?

NCT00250159 is a clinical study titled "Natural History Study of Patients With Excess Androgen". This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effects of too much androgen and describe problems associated with it. Too much androgen in childhood, if untreated, results in rapid growth and ...

What is the current status of trial NCT00250159?

This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2006-01-02.

What conditions does trial NCT00250159 study?

This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia (CAH), Familial Male-Limited Precocious Puberty (FMPP).

Who is sponsoring clinical trial NCT00250159?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00250159 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Adrenal Hyperplasia (CAH)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.